According to Dimsum Daily, systematic lupus erythematosus (lupus) is one of the most common systematic autoimmune diseases. It is widely prevalent in China with over one million active patients.

AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before ...

People with lupus should avoid certain supplements, including spirulina, vitamin E, and echinacea, to decrease the risk of flare-ups of symptoms. However, other supplements may benefit someone ...

Systemic Lupus Erythematosus companies are GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb ...

Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life. Damage resulting from the disease and ...

The systemic lupus erythematosus-associated NCF1 90H allele synergizes with viral infection to cause mouse lupus but also limits virus spread The induction of autoimmune symptoms may require both ...

Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLEGAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC ...

Lupus does not have a cure, whether through medication or natural treatments. However, people may find that certain herbs, supplements, and mind-body therapies help reduce the symptoms. Lupus ...

Systemic lupus erythematosus is an incurable chronic autoimmune disease marked by systemic inflammation that affects multiple organ systems including the skin, joints, kidneys, brain, and heart. The ...

AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before ...

--Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 ...